实用肝脏病杂志 ›› 2026, Vol. 29 ›› Issue (5): 705-708.doi: 10.3969/j.issn.1672-5069.2026.05.017

• 肝硬化 • 上一篇    下一篇

肝病专用型肠内营养制剂治疗失代偿期乙型肝炎肝硬化患者临床疗效研究*

陈丽虹, 刘银辉, 高梅芳, 李品娣, 吴伟新, 张玮, 李洪昌   

  1. 528100 广东省佛山市 南方医科大学珠江医院三水医院感染内科(陈丽虹,刘银辉,高梅芳,吴伟新,张玮);临床营养科(李洪昌,李品娣)
  • 收稿日期:2025-04-30 发布日期:2026-09-14
  • 通讯作者: 李洪昌,E-mail:yonex88@163.com
  • 作者简介:陈丽虹,女,44岁,大学本科,副主任医师。E-mail:13724630717@163.com
  • 基金资助:
    广东省自然科学基金资助项目(编号:2022A1515220188)

Clinical efficacy of enteral nutrition preparations in the treatment of patients with decompensated hepatitis B-induced liver cirrhosis

Chen Lihong, Liu Yinhui, Gao Meifang, et al   

  1. Department of Infectious Diseases, Sanshui Hospital, Affiliated to Zhujiang Hospital, Southern Medical University, Foshan 528100, Guangdong Province, China
  • Received:2025-04-30 Published:2026-09-14

摘要: 目的 观察应用肝病专用型肠内营养制剂治疗失代偿期乙型肝炎肝硬化患者的临床疗效。方法 2023年1月~2024年5月佛山市三水区人民医院收治的80例失代偿期乙型肝炎肝硬化患者,被分成对照组40例和观察组40例,在内科综合治疗的基础上,给予对照组整蛋白型肠内营养制剂治疗,给予观察组肝病专用型肠内营养制剂治疗,两组均治疗6个月。常规检测血常规、血生化和血清肝纤维化指标。结果 在治疗6个月末,对照组死亡2例,观察组死亡1例;观察者生存者血清白蛋白水平为(35.7±5.4)g/L,显著高于对照组【(31.1±4.6)g/L,P<0.05】,而血清总胆红素水平为(22.6±8.1)μmol/L,显著低于对照组【(28.9±9.7)μmol/L,P<0.05】; 观察组红细胞计数和血红蛋白水平分别为(4.1±1.4)×1012/L和(108.5±6.9)g/L,均显著高于对照组【分别为(3.8±1.6)×1012/L和(98.2±5.8)g/L,P<0.05】;观察组血清HA和Ⅳ-C水平分别为(123.6±15.0)μg/L和 (135.0±47.8)μg/L,均显著低于对照组【分别为(151.4±16.0)μg/L和(158.7±46.1)μg/L,P<0.05】。结论 应用肝病专用型肠内营养制剂口服治疗能够显著改善患者的营养状态,表现为贫血改善,血清白蛋白水平提高,值得临床应用。

关键词: 肝硬化, 失代偿期, 肝病专用型肠内营养制剂, 治疗

Abstract: Objective The aim of this study was to investigate clinical efficacy of enteral nutrition preparations in the treatment of patients with decompensated hepatitis B-induced liver cirrhosis (LC). Methods 80 patients with decompensated hepatitis B-induced LC were encountered in Sanshui District People's Hospital, Foshan City between January 2023 and May 2024, all patients were carefully managed with comprehensive internal medication, and were randomly assigned to receive general whole-protein enteral nutrition preparations in 40 cases in control group, or to receive enteral special nutrition preparations in another 40 cases in observation group for six months. Blood, biochemical and serum liver fibrosis markers were routinely screened. Results By end of six-month treatment, two patients in the control and one patient in the observation died; serum albumin level in the observation survivals was (35.7±5.4)g/L, much higher than [(31.1±4.6)g/L, P<0.05], while total serum bilirubin level was (22.6±8.1)μmol/L, much lower than [(28.9±9.7)μmol/L, P<0.05] in control survivals; red blood cell count and hemoglobin level were (4.1±1.4)×1012/L and (108.5±6.9)g/L, both significantly higher than [(3.8±1.6)×1012/L and (98.2±5.8)g/L, respectively, P<0.05] in the control; serum hyaluronic acid and type IV collagen levels were (123.6±15.0)μg/L and (135.0±47.8)μg/L, both significantly lower than [(151.4±16.0)μg/L and (158.7±46.1)μg/L, respectively, P<0.05] in the control group. Conclusion The additional oral supplement with liver disease-special enteral nutrition preparations in dealing with patients with decompensated hepatitis B-induced LC could ameliorate anemia and hypoproteinemia, which merits further clinical investigation.

Key words: Liver cirrhosis, Decompensated liver functions, Liver disease-specific enteral nutrition preparation, Therapy